Loading...
Market
In which region will the new Alzheimer's drug clinical trials first commence by the end of 2025?
2
Resolution / Starting Odds
Russia • 25%
Europe (excluding Russia) • 25%
North America • 25%
Asia (excluding Russia) • 25%
Official announcements from the drug developers or regulatory bodies
Story
New Drug Completes Preclinical Stage, Offers Hope for Rapid Alzheimer's Diagnosis
Oct 18, 2024, 09:18 AM
A new drug developed by specialists from Russian Peter the Great St. Petersburg Polytechnic University aims to protect Alzheimer's patients from memory loss. The drug's main substance, piperazine, is designed to target the brain effectively and has completed the preclinical stage. This development comes amid ongoing efforts to improve dementia diagnosis and treatment. Currently, it takes more than seven years on average to diagnose dementia, but new tests offer hope for rapid diagnosis. Experts are also exploring the potential of 'repurposed' drugs to limit the progression of dementia.
View original story
Similar markets
United States • 25%
European Union • 25%
South Korea • 25%
Other • 25%
North America • 25%
Europe • 25%
Asia • 25%
Other • 25%
North America • 25%
Europe • 25%
Asia • 25%
Other • 25%
Mayo Clinic • 25%
Cleveland Clinic • 25%
Johns Hopkins • 25%
Other • 25%
Australia • 25%
United States • 25%
United Kingdom • 25%
Germany • 25%
United States • 25%
European Union • 25%
China • 25%
Other • 25%
North America • 25%
Europe • 25%
Asia • 25%
Other • 25%
United States • 25%
European Union • 25%
China • 25%
Other • 25%
Statistically significant improvement • 25%
No significant difference • 25%
Worse outcomes • 25%
Trial terminated early • 25%
0-1 • 25%
2-5 • 25%
6-10 • 25%
More than 10 • 25%
Sub-Saharan Africa • 25%
Southeast Asia • 25%
South America • 25%
Other • 25%